MonTa Biosciences announces today that our phase I study has obtained regulatory and ethical approval in both Spain and Belgium. This is of great importance and means we will be able to recruit patients much faster for our upcoming expansion cohort of our study. We have been able to identify and initiate collaboration with very strong Key Opinion Leaders in both Spain and Belgium, and the investigators look forward to provide the MBS8 treatment for patients at their clinics.